Daewon Pharmaceutical has strengthened its cosmetics business by hiring a dermocosmetics expert. This appointment is seen as part of a broader effort to restructure its subsidiary.
On June 16, Daewon Pharmaceutical announced the appointment of Kim Hye-won, former executive director at CMS Lab, as the new CEO of its subsidiary, SD BioScience.
Kim brings 26 years of experience from leading beauty companies in South Korea, including Amorepacific, Neopharm, and CMS Lab, where she held various roles in planning, marketing, sales, and research. The company plans to leverage her expertise to revamp its brand portfolio and enhance distribution capabilities both domestically and internationally, aiming for significant growth in the cosmetics sector.
SD BioScience was acquired to diversify its operations across pharmaceuticals, health supplements, and cosmetics. However, the company has faced financial challenges, reporting operating losses of 9.2 billion won in 2024 and 6.3 billion won last year.
Kim stated, "I will systematize the business structure through a multifaceted assessment of current distribution channels and a product-centered sales and marketing strategy. I will focus on building a sustainable growth pipeline for SD BioScience based on my extensive ODM network and experience in designing new business cycles."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.